Johnson & Johnson $JNJ Stock Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 7.2% in the third quarter, Holdings Channel reports. The firm owned 1,159,486 shares of the company’s stock after selling 89,858 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Johnson & Johnson were worth $306,962,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in JNJ. Wellington Management Group LLP grew its stake in shares of Johnson & Johnson by 12.5% in the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock valued at $5,736,851,000 after buying an additional 2,513,321 shares in the last quarter. Deutsche Bank AG increased its holdings in Johnson & Johnson by 8.5% during the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after buying an additional 1,225,676 shares during the last quarter. Amundi increased its holdings in Johnson & Johnson by 17.5% during the first quarter. Amundi now owns 13,406,820 shares of the company’s stock worth $3,277,163,000 after buying an additional 2,001,139 shares during the last quarter. Jupiter Topco LLC bought a new stake in Johnson & Johnson during the second quarter worth $1,967,399,000. Finally, Janus Henderson Group PLC raised its position in Johnson & Johnson by 1.9% during the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock worth $1,924,323,000 after acquiring an additional 148,497 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 1.4%

JNJ stock opened at $272.49 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The company has a fifty day moving average price of $265.71 and a two-hundred day moving average price of $248.01. Johnson & Johnson has a one year low of $185.12 and a one year high of $282.02. The stock has a market cap of $655.97 billion, a price-to-earnings ratio of 41.29, a price-to-earnings-growth ratio of 2.73 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the company earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Equities analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio is 81.21%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: State Street’s Health Care SPDR added J&J shares as part of a $175.3 million purchase across its portfolio, providing a modest institutional-demand signal. Article: State Street Health Care SPDR Adds Eli Lilly and J&J
• Positive Sentiment: One analyst roundup described Wall Street as moderately bullish on J&J’s prospects, following the stock’s strong performance over the past year. Article: Are Wall Street Analysts Predicting Johnson & Johnson Stock Will Climb or Sink?
• Neutral Sentiment: Several articles highlighted J&J as a long-term dividend stock, including lists of companies with long records of annual payout increases. This supports its income-investment appeal, but the pieces offer no new company-specific dividend announcement. Article: 4 Dividend Kings That Could Pay You for the Rest of Your Retirement
• Neutral Sentiment: A value-investing comparison examined J&J alongside Bayer, while another article addressed concerns that J&J shares may look expensive; the supplied headlines do not specify a valuation conclusion. Article: BAYRY vs. JNJ: Which Stock Is the Better Value Option?
• Negative Sentiment: Smith+Nephew said merger discussions with J&J’s orthopaedics unit had failed. This removes a potential transaction, though the article headline provides no details on the talks’ terms or financial implications for J&J. Article: Smith+Nephew Cuts Outlook, Confirms Failed Merger Talks with J&J’s Orthopaedics Unit

Insider Activity

In other news, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Jennifer L. Taubert sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. The SEC filing for this sale provides additional information. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on JNJ. Citigroup lifted their price objective on shares of Johnson & Johnson from $298.00 to $303.00 and gave the company a “buy” rating in a research report on Monday, October 5th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $282.00 target price on shares of Johnson & Johnson in a report on Thursday, July 16th. Guggenheim reiterated a “buy” rating and issued a $287.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 7th. UBS Group set a $270.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 14th. Finally, Evercore set a $300.00 price target on Johnson & Johnson in a report on Tuesday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.92.

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.